US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.32 against a street estimate of 0.93 — a beat of 41.9%.
Analysts rate Indivior PLC Ordinary Shares a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $49.50.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.85% |
| Vanguard Portfolio Management, LLC | 6.42% |
| Oaktree Capital Management LLC | 5.19% |
| Vanguard Capital Management, LLC | 4.66% |
| State Street Corp | 4.23% |
| Two Seas Capital LP | 4.02% |
| Fuller & Thaler Asset Management Inc | 3.91% |
| Morgan Stanley - Brokerage Accounts | 2.88% |
| Document | Date |
|---|---|
| Company announcement · Q4 2026 HEADLINE NUMBERS • Supernus increased the conversion rate on its 0.625% Convertible Senior Notes due 2031 from 24.0033 shares to 30.9355 shares per $ | 2026-11-03 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • On November 2, 2026, Indivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals. • Indivior was renamed Supernus | 2026-11-02 |
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net revenue was $356 million, up from $314 million in third-quarter 2025. Nine-month revenue was $1,016 million | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total net revenue was $356 million, up 13% year over year from $314 million. • Q3 2026 net income was $137 million, or $1 | 2026-10-29 |
| Shareholder vote results · Q4 2026 HEADLINE NUMBERS • Indivior held a special stockholder meeting on October 15, 2026, regarding the proposed merger. • The company’s stockholders appr | 2026-10-15 |
| Company announcement · Q4 2026 MERGER UPDATE • Indivior and Supernus plan to combine under an August 1, 2026 merger agreement. • Indivior will be renamed Supernus, Inc., with Supe | 2026-10-06 |
| Reg FD disclosure · Q3 2026 INDIVIOR PHARMACEUTICALS, INC. – FORM 8-K SUMMARY Filed September 17, 2026 --- HEADLINE NUMBERS • Special cash dividend declared: $8.13 per share o | 2026-09-17 |
| Current report · Q3 2026 INDIVIOR PHARMACEUTICALS, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Indivior manufactures and supplies SUBOXONE® Tablets and SUBUTEX® | 2026-09-15 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $8.13 / share ex-date Nov 3, 2026 · pay Nov 6, 2026 | 2026-11-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Indivior PLC Ordinary Shares — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.